Castleark Management’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-292,850
| Closed | -$9.46M | – | 352 |
|
|
2021
Q3 | $9.46M | Sell |
292,850
-1,540
| -0.5% | -$51.1K | 0.36% | 79 |
|
|
2021
Q2 | $9M | Buy |
294,390
+15,355
| +6% | +$444K | 0.3% | 93 |
|
|
2021
Q1 | $8.5M | Buy |
+279,035
| New | +$7.92M | 0.31% | 96 |
|
|
2020
Q4 | – | Sell |
-240
| Closed | -$3K | – | 357 |
|
|
2020
Q3 | $3K | Hold |
240
| – | – | ﹤0.01% | 341 |
|
|
2020
Q2 | $3K | Hold |
240
| – | – | ﹤0.01% | 334 |
|
|
2020
Q1 | $3K | Hold |
240
| – | – | ﹤0.01% | 335 |
|
|
2019
Q4 | $7K | Hold |
240
| – | – | ﹤0.01% | 340 |
|
|
2019
Q3 | $7K | Sell |
240
-21,000
| -99% | -$612K | ﹤0.01% | 346 |
|
|
2019
Q2 | $590K | Sell |
21,240
-1,520
| -7% | -$42.9K | 0.02% | 280 |
|
|
2019
Q1 | $756K | Hold |
22,760
| – | – | 0.03% | 276 |
|
|
2018
Q4 | $662K | Hold |
22,760
| – | – | 0.03% | 278 |
|
|
2018
Q3 | $1.05M | Hold |
22,760
| – | – | 0.03% | 293 |
|
|
2018
Q2 | $851K | Hold |
22,760
| – | – | 0.03% | 285 |
|
|
2018
Q1 | $673K | Hold |
22,760
| – | – | 0.02% | 294 |
|
|
2017
Q4 | $782K | Sell |
22,760
-422,875
| -95% | -$14.3M | 0.02% | 301 |
|
|
2017
Q3 | $16.1M | Buy |
445,635
+422,875
| +1,858% | +$12.1M | 0.51% | 51 |
|
|
2017
Q2 | $588K | Hold |
22,760
| – | – | 0.02% | 302 |
|
|
2017
Q1 | $437K | Hold |
22,760
| – | – | 0.01% | 316 |
|
|
2016
Q4 | $379K | Hold |
22,760
| – | – | 0.01% | 322 |
|
|
2016
Q3 | $468K | Hold |
22,760
| – | – | 0.01% | 310 |
|
|
2016
Q2 | $696K | Sell |
22,760
-218,654
| -91% | -$7.6M | 0.02% | 297 |
|
|
2016
Q1 | $9.04M | Sell |
241,414
-65,986
| -21% | -$2.49M | 0.28% | 90 |
|
|
2015
Q4 | $13.3M | Sell |
307,400
-8,070
| -3% | -$341K | 0.4% | 64 |
|
|
2015
Q3 | $11.8M | Buy |
315,470
+289,230
| +1,102% | +$10.3M | 0.38% | 68 |
|
|
2015
Q2 | $892K | Hold |
26,240
| – | – | 0.02% | 308 |
|
|
2015
Q1 | $929K | Hold |
26,240
| – | – | 0.02% | 290 |
|
|
2014
Q4 | $894K | Sell |
26,240
-260
| -1% | -$9.23K | 0.02% | 267 |
|
|
2014
Q3 | $906K | Hold |
26,500
| – | – | 0.03% | 249 |
|
|
2014
Q2 | $1.03M | Hold |
26,500
| – | – | 0.03% | 238 |
|
|
2014
Q1 | $906K | Hold |
26,500
| – | – | 0.03% | 249 |
|
|
2013
Q4 | $556K | Buy |
26,500
+260
| +1% | +$6.58K | 0.02% | 271 |
|
|
2013
Q3 | $1.01M | Sell |
26,240
-5,060
| -16% | -$144K | 0.03% | 244 |
|
|
2013
Q2 | $841K | Buy |
+31,300
| New | +$907K | 0.03% | 240 |
|
Other funds holding MYGN
CCM
PHS
Castleark Management's MYGN Position: Q4 2021 in Review
Castleark Management sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 292,850 shares — an estimated $9.46M sold.
Castleark Management first reported a position in MYGN in Q2 2013 and held it in 33 quarters. The position peaked at $16.1M in Q3 2017. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.
- Castleark Management reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
- Castleark Management sold 292,850 Myriad Genetics shares in Q4 2021, an estimated $9.46M.
- Castleark Management first reported a position in Myriad Genetics in Q2 2013 and held it in 33 quarters.
- Castleark Management's Myriad Genetics position peaked at $16.1M in Q3 2017.
- 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.
Based on Castleark Management's 13F filing for Q4 2021, filed 16 Feb 2022.